Satellite company AST SpaceMobile expects to close SPAC deal next week and begin trading on Nasdaq

Investing

In this article

AST’s corporate headquarters and high-volume manufacturing facility in Midland, Texas
AST & Science

Satellite-to-smartphone broadband company AST & Science expects to close its SPAC merger next week, the company said on Thursday. Its stock will trade on the Nasdaq.

Last year, the company announced plans to merge with special purpose acquisition company New Providence, which trades under ticker NPA.

Stockholders voted on Thursday to approve the transaction, with the closing expected “on or about April 6,” or next Tuesday. The combined company of AST & Science and New Providence will be known as AST Space Mobile, and will trade under the ticker ASTS.

New Providence’s stock slipped more than 4% in midday trading from its previous close of $11.67 a share.

AST SpaceMobile, based in Midland, Texas, is building a network of satellites, also known as a constellation, that is designed to deliver broadband from space directly to consumer smartphones. Existing satellite networks require additional physical devices to connect to the service, such as Iridium’s mobile satellite phones or SpaceX’s Starlink user terminals.

The company, which raised about $120 million before the SPAC deal, expects to add about $462 million in total proceeds from the merger. The new capital will fund the company’s development of its network, with AST planning to launch its next demonstration satellite BlueWalker 3 later this year.

AST’s expected close would come as the first of a recent series of space SPAC’s to complete its merger. Including AST, seven space companies have announced deals with SPAC’s in the past six months.

Articles You May Like

Goodbye to Berlin, Europe’s self-effacing capital
Munis outperform UST losses, sit back after large selloff
Defaults on leveraged loans soar to highest in 4 years
The Fed cut interest rates but mortgage costs jumped. Here’s why
Matt Gaetz accused of paying for sex and using drugs by US congressional panel